<div id="readability-page-1">02:39 PM EDT, 05/14/2026 (MT Newswires) -- (Updates with latest stock price movement in the headline and first paragraph, Q1 earnings in the second through sixth paragraphs.)Regenxbio's ( RGNX ) shares were down about 36% in Thursday afternoon trading after its Q1 swung to a loss and revenue declined.The company reported a Q1 net loss Thursday of $1.72 per diluted share, swinging from earnings of $0.12 a year earlier.Analysts polled by FactSet expected a loss of $1.34.Revenue for the quarter ended March 31 fell to $6.4 million from $89.0 million a year earlier.Analysts surveyed by FactSet expected $25.8 million.The company expects its cash, cash equivalents and marketable securities of $150.5 million as of March 31 to fund its operations into early 2027.Separately, the company said Thursday its investigational gene therapy RGX-202 met the primary endpoint in the pivotal phase III portion of the Affinity Duchenne trial for Duchenne Muscular Dystrophy.The company said 93% of patients achieved over 10% microdystrophin expression at week 12.Regenxbio ( RGNX ) said it is preparing to pursue accelerated approval based on the data and is targeting a potential commercial launch in 2027.Price: 6.47, Change: -3.57, Percent Change: -35.56 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

RGNX

LABU

SBIO

IBBQ

Regenxbio's shares fell 36% after reporting a Q1 net loss of $1.72 per diluted share, down from earnings of $0.12 a year earlier. Revenue dropped to $6.4 million from $89.0 million, missing analyst expectations. The company has $150.5 million in cash to fund operations into early 2027. However, its gene therapy RGX-202 met primary endpoints in a Phase 3 trial, with plans for accelerated approval and a potential commercial launch in 2027.

fidelity

Regenxbio

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

Factset Research

Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary Endpoint